ASCO® recommends fusion testing when:
there are FDA-approved fusion-targeted therapies for that specific disease, as well as testing for other fusions if no other variants are identified on panel-based DNA sequencing2
Expert report consultation at your convenience
Our medical team brings 20+ years of experience in genomic oncology—and is available to help with interpreting test results
IHC, immunohistochemistry; MSI, microsatellite instability; TMB, tumor mutational burden.
-
References
Streamlined, actionable insights for timely decision-making
For patients with advanced cancer, timely knowledge is crucial. The OncoExTra report highlights the most clinically relevant information, to support prompt, point-of-care discussions between oncologists and their patients, leading to shared treatment decisions.1*
*Select immunohistochemical (IHC) panels and single stains are offered as an optional add-on. IHC not currently available in New York State.
†The OncoExTra test is not an FDA-cleared or -approved IVD device or companion diagnostic for the referenced biomarkers and FDA-approved therapies.
 |
Discover variants and fusions associated with FDA-approved treatments†A snapshot of variants and fusions delivers an ultra-comprehensive genomic picture, while providing information about treatment options and their levels of evidence
|
 |
See tumor mutational burden and microsatellite instabilityImmuno-oncology signatures (TMB/MSI) support truly individualized decisions
|
 |
Find clinical trial options for your patientPairing your patients’ genomic results with potential clinical trials helps provide more treatment opportunities. Clinical trials will be noted here with detailed information on later pages.
|
 |
Add on IHC testing*Optional IHC tests are available, including 3 PD-L1 clones (SP142, 22C3, SP263), MMR (Mismatch Repair) proteins and preselected tumor-specific panels |
ASCO® recommends fusion testing when:
there are FDA-approved fusion-targeted therapies for that specific disease, as well as testing for other fusions if no other variants are identified on panel-based DNA sequencing2
Actionable results within 14 days of sample submission receipt1
Results provided via fax or through our secure, intuitive online Provider Hub
Expert report consultation at your convenience
Our medical team brings 20+ years of experience in genomic oncology—and is available to help with interpreting test results
IHC, immunohistochemistry; MSI, microsatellite instability; TMB, tumor mutational burden.
-
References